In addition to serving a role as a DNA bindingdependent transcriptional activator, p53 has been reported to repress a variety of promoters that lack p53 binding sites. Data from recent studies have suggested that this activity is mediated via an interaction between p53 and the TATA box binding protein (TBP). To investigate the functional relevance of this interaction in vivo, we have performed transient transfection assays in Drosophila Schneider cells. Wild-type p53 was found to repress expression from TATA box-but not initiator (Inr)-containing promoters activated by GAL4-VP16, GAL4-ftzQ or Sp1. A mutant p53 (His175) , defective in DNA binding and transcriptional activation, also inhibited TATA-dependent transcription activated by Sp1. However, p53 was unable to repress a basal TATA promoter stimulated by overexpression of TBP. Furthermore, overexpression of TBP failed to rescue the p53-mediated repression of activated transcription and a p53 mutant with its N-terminal TBP interaction domain intact, but defective in transcriptional activation and binding to TBP-associated factors (TAFs), was similarly defective in transcriptional repression. These data suggest that a p53-TBP interaction is not sufficient for transcriptional repression by p53 and that repression involves an interaction between p53 and other factors, such as TAFs, that are required for activated but not basal transcription. We suggest that p53-mediated repression results from squelching of a factor limiting for activated transcription from TATAbut not Inr-containing promoters.
INTRODUCTION
The p53 tumor suppressor protein can transmit signals from agents of genotoxic stress to genes that control the cell cycle and apoptosis (reviewed in [1] [2] [3] [4] . The most well-documented function of p53 is its ability to activate transcription from promoters containing p53 response elements (5, 6) . There are a number of likely p53 target genes that have been identified, including GADD45 (7), mdm2 (8) , p21/WAF1 (9), cyclin G (10, 11) , bax (12) and IGFBP3 (13) . These genes and others have been shown to contain one or more versions of the p53 consensus binding site, to be activated in wild-type p53-containing cells after DNA damage and, in some cases, to have properties consistent with the growth suppression function of p53. Many studies have demonstrated that p53 is also capable of repressing transcription (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) . In contrast to activation by p53, however, no common consensus sequence is present in genes that are repressed by p53. Yet there are a number of studies suggesting that in some cells p53 is capable of inducing apoptosis by a transactivation-independent mechanism (32) (33) (34) . Understanding the mechanism of transcriptional repression by p53 may therefore provide insight into its function in cells.
A number of transcription factors have been shown to physically interact with p53, including the TATA box binding protein (TBP) (19, (35) (36) (37) and TBP-associated factors, Drosophila TAF II 40 and TAF II 60 and the corresponding human factors TAF II 31 and TAF II 70 (38,39) . Mutation of two specific N-terminal residues in p53 (residues Leu22 and Trp23) impairs the ability of p53 to transactivate (40) and has been correlated with its ability to bind TAF II 40 and TAF II 60 (or TAF II 31 and TAF II 70) (38, 39) , suggesting that one or both of these interactions is important for activation. Mutation of residues 22 and 23 to Ala does not affect binding to TBP (40, 41) , although mutation of these residues to charged amino acids was reported to disrupt the p53-TBP interaction (42) .
Sequence analysis of TBP cloned from a number of species has revealed the presence of a non-conserved N-terminal domain and a highly conserved C-terminal domain (for a review see 43) . Through the use of deletion mutants consisting of only the conserved C-terminal domain of TBP, the C-terminus alone has been shown to embody all of the known properties of TBP, including TATA box binding, TAF interactions and transcriptional activation (44) . Using other methods, this domain has also been shown to bind several transcriptional activators (see for example [45] [46] [47] including p53 (35, 48) , although the functional importance of these interactions has yet to be shown.
Studies demonstrating that p53 can repress basal transcription in vitro have implicated TBP as a target in this activity (19, 23) , consistent with the observation that p53 repression requires the presence of a TATA box within the promoter (22) . To gain more insight into the factors involved in p53-mediated repression, we describe experiments investigating repression by p53 in transfected Drosophila Schneider cells. Our results demonstrate that a p53-TBP interaction is insufficient for repression and suggest that an alternative pathway(s) exists that involves interactions between p53 and other factors, such as TAFs.
MATERIALS AND METHODS

Transient transfection assays
All exogenously expressed proteins were expressed under the control of the Drosophila actin 5C promoter, designated pACT (49) . Experiments were repeated three or four times and the best results obtained are described in the accompanying Figures. pACT53, originally described by Chen et al. (50) , expresses wild-type human p53, pACTmtp53 expresses the human mutant p53 (Ala22,Ala23) , originally described by Lin et al. (40) , and pACThis175 expresses tumor-derived mutant p53 (His175) , originally described by Baker et al. (51) . pACTdTBP (52) and pACTThTBP express Drosophila TBP and HA epitope-tagged (53) human TBP respectively. pACTSp1 (52), pACTG4ftzQ and pACTG4VP16 (54) were constructed to express human Sp1 and the hybrid activators GAL4-ftzQ and GAL4-VP16 respectively.
Transfection of Schneider cells was performed essentially as described (49, 52) . The total actin 5C expression plasmid (pACTPPA) in each tube was adjusted to 7 µg by addition of the actin 5C expression plasmid without any insert. All DNA mixtures also contained 2 µg copia-lacZ plasmid to monitor transcription efficiencies and 2 µg CAT reporter plasmids. A modified 2× HEBS solution (280 mM NaCl, 7 mM KCl, 1.25 mM Na 2 HPO 4 , 0.2% dextrose, 40 mM HEPES, pH 7.1) was used instead of that previously described (49) . All solutions were used at room temperature. Addition of the DNA/calcium chloride mixtures proceeded as a gentle stream of air was administered to the HEBS solution via a 10 µl glass pipette to precipitate the DNA. After sitting at room temperature for 10 min, the suspensions of DNA (total volume ∼700 µl) were added to the 60 mm plates containing the Schneider cells and gently agitated. After a 48 h incubation the cells were lysed and assayed for β-galactosidase activity as previously described (49) .
To determine the amount of extract to be used in the subsequent CAT assays, all volumes were normalized to 40 µl extract by comparison with that which revealed the lowest level of β-galactosidase activity. Before use CAT extracts were diluted in 200 mM Tris, pH 8.0, plus 100 µg/ml bovine serum albumin (Sigma) to ensure that subsequent scintillation counts were in the linear range. Corresponding volumes of extract were added to 7 ml glass scintillation vials and 200 µl CAT reaction mixture [1.5 mM chloramphenicol (in water), 125 µM cold acetyl CoA (Sigma), 0.63 µCi/ml [ 3 H]acetyl-CoA (Amersham), 1 mM EDTA and 10 mM Tris, pH 8.0] were added to each vial at 40 s intervals. One blank was prepared without extract to determine background activity. Aliquots of 5 ml Econo-Flur scintillation fluid (DuPont) was added to each vial, capped and allowed to sit for 3 h at room temperature before scintillation counting. Three separate rounds of 30 s counts/vial were made and averaged together. Values were adjusted depending on the dilution previously made of the extracts used in the assays.
Determination of protein expression from Schneider cells
Cells were transfected as described before with the appropriate expression plasmids. After a 48 h incubation period, cells were harvested and washed as previously described and resuspended in 200 µl 1× protein sample buffer (3% glycerol, 100 mM β-mercaptoethanol, 0.5% SDS, 100 mM Tris, pH 6.8). Aliquots of 50 µl of the cell suspensions were loaded onto 10% polyacrylamide gels (38:0.8 acrylamide:bis acrylamide, 0.1% SDS, 750 mM Tris, pH 8.3). Detection of flu-tagged hTBP and p53 was done using the 12CA5 monoclonal antibody (53) and p53 monoclonal antibody PAb 421 respectively, via Western blot analysis and the ECL detection system (Amersham).
RESULTS
Wild-type p53, as well as a tumor-derived mutant p53 (His175) , inhibits activated transcription from TATA-containing, but not TATA-lacking, promoters in transfected Drosophila Schneider cells In order to investigate the possible significance of the p53-TBP interaction in p53-mediated transcriptional repression, we chose to use Drosophila Schneider cells in transient transfection assays. These cells were chosen because they do not contain a homolog of p53 (55) and also because they have proven useful for studying transcriptional phenomena in vivo (41, 52, 54, 56, 57) . All experiments utilized detection of chloramphenicol acetyltransferase (CAT) activity as the measure of transcriptional activity. Data points were all repeated at least twice in separate experiments, although the majority were performed multiple times, in some cases up to 10. While the levels of CAT expressed varied in different batches of Schneider cells, the overall effects (or lack thereof) in each case were remarkably consistent. Thus all experiments shown in this study are typical of and consistent within a number of trials. Transient transfections were conducted with increasing amounts of a plasmid expressing wild-type human p53 from the Drosophila actin 5C promoter (pACT53; 50) and constant amounts of similar expression plasmids for either GAL4-VP16, GAL4-ftzQ or Sp1 (52, 54) . For experiments employing GAL4-VP16 and GAL4-ftzQ, transcriptional activity was measured from a cotransfected CAT reporter construct bearing five GAL4 binding sites upstream of the adenovirus E1B TATA box (G5-E1B-CAT; 54). For experiments employing Sp1, activity was measured from a reporter construct containing three Sp1 sites substituted for the five GAL4 binding sites (SV-E1B-CAT; 52). Amounts of the activator expression plasmids were adjusted to yield equivalent amounts of CAT expression, which were of the order of 10 000-fold over basal levels (data not shown). After co-transfection of increasing amounts of pACT53, the ability of GAL4-VP16, GAL4-ftzQ and Sp1 to stimulate CAT expression from their respective promoter constructs was significantly inhibited (Fig. 1 ). This effect was not due to p53 inhibiting expression of the transactivators from the actin 5C promoter (see below). Moreover, the inhibition was specific for activated transcription from the CAT expression plasmids, since activity from the β-galactosidase expression plasmid (copia-lacZ) used to monitor transfection efficiency was not significantly affected (date not shown).
The reporter plasmid utilized in the above experiments lacked known p53 binding sites, suggesting that repression does not require DNA binding by p53. If this is the case then a DNA binding-defective p53 mutant might retain repression activity. To test this, a tumor-derived mutant human p53 (His175) , incapable of suppressing cell growth in tissue culture (51), binding to DNA (58, 59 ) and activating transcription in mammalian cells in vivo and in vitro (60, 61) , was employed. Transient expression of 001 µg pACTSP1 (expressing Sp1; closed circles), which yielded an ∼10 000-fold stimulation of CAT activity over basal levels from either 2 µg G5-E1B-CAT (for GAL4-VP16 and GAL4-ftzQ) or 2 µg SV-E1B-CAT (for Sp1), were used. Aliquots of 2 µg of the TATA-containing reporter plasmids (G5-E1B-CAT and SV-E1B-CAT) were transfected with the activator expression plasmids either alone or with increasing amounts of pACT53-expressing wild-type human p53. y-axis values represent the relative CAT activity due to transfection of the transactivator expression plasmids in the absence of pACT53.
p53 (His175) in Schneider cells revealed that this mutant was just as effective as wild-type in repressing CAT expression activated by Sp1 from SV-E1B-CAT ( Fig. 2A) . This result was not due to p53 (His175) assuming a wild-type conformation at the incubation temperature of 25_C used in our experiments as the protein is incapable of DNA binding site-dependent transcriptional activation in Schneider cells (Fig. 2B, upper panel) . Moreover, mutant p53 (His175) was expressed at a similar level to that of wild-type p53 in transfected Schneider cells (Fig. 2B, lower panel) . These results demonstrate that DNA binding is not required for transcriptional repression and that repression activity does not correlate with the ability of p53 to suppress cell growth.
Mack et al. (22) demonstrated, in HeLa cell transient transfection assays, that while p53 could repress activity from a promoter bearing a TATA box, it could not do so from one containing an initiator sequence (Inr) as its only basal promoter element. To investigate this phenomenon in more detail, we employed a variety of activators to measure the effect of p53 on their activity on a number of reporter plasmids in Schneider cells. As shown in Figure 3A , all three of the transcriptional activators mentioned above activated CAT expression from their respective reporter constructs, containing either the adenovirus E1B TATA box (G5-E1B-CAT or SV-E1B-CAT) or the terminal deoxytransferase initiator (G5-INR-CAT or SV-INR-CAT; 52) as their basal elements. Using similar amounts of expression plasmids for the various transcriptional activators, we observed that the level of CAT activity due to expression of GAL4-VP16 was about seven times higher from the TATA-containing plasmid than from the Inr-containing plasmid, while the level of CAT activity due to expression of GAL4-ftzQ was ∼14 times higher from the TATA-containing plasmid than from the Inr-containing plasmid. In contrast, the level of CAT activity due to expression of Sp1 was slightly higher from the Inr-containing plasmid. Despite these differences, transfection of pACT53 had minimal effects on activated CAT expression from G5-INR-CAT and SV-INR-CAT, while strongly inhibiting expression from G5-E1B-CAT and SV-E1B-CAT (Fig. 3B) . In addition to confirming that Inrcontaining promoters can be resistant to p53-mediated repression, this observation also argues strongly against the possibility that p53 exerted its repressive effects by inhibiting expression of the other transactivators from their respective expression plasmids. This is our best evidence that p53 expression does not affect protein expression of the various transactivators, since the amounts of transactivator expression plasmids used in these experiments were too low to allow detection of the corresponding proteins. These results therefore extend those obtained previously demonstrating that p53 specifically represses promoters containing a TATA box as its only basal promoter element (22) . Since transcription from Inr-containing promoters also requires TBP (62), these results are consistent with the possibility that p53 mediates its repressive effects by interacting with a factor(s) in addition to, or distinct from, TBP.
p53 does not inhibit basal transcription stimulated by overexpression of TBP
Data from previous reports suggested that p53 mediates repression via a direct interaction with TBP in vitro (19, 23) and in vivo (48) . To further investigate this possibility in vivo, we took advantage of a previous observation that overexpression of Drosophila TBP (dTBP) in Schneider cells can stimulate basal transcription from a construct bearing a TATA box as its only basal promoter element (52) . We have previously shown that dTBP and either a p53-GAL4 fusion protein or intact wild-type p53 can synergistically activate transcription from CAT reporter plasmids containing either GAL4 or p53 binding sites respectively (41, 50) . Since this demonstrated a functional interaction between p53 and dTBP, we were interested to see what effect p53 would have on the stimulation of basal CAT activity by overexpressed TBP in the absence of p53 binding sites. Expression of either dTBP or human TBP (hTBP) stimulated basal CAT expression from G5-E1B-CAT 40-and 6-fold respectively (data not shown). It is likely that the difference in activity is due to differences in protein accumulation in the transfected cells (data not shown). Nevertheless, transfection of increasing amounts of pACT53 had no significant effect, positive or negative, on stimulation by either version of TBP (Fig. 4A) . Furthermore, transfection of pACT53 had no effect on the low levels of basal activity from G5-E1B-CAT in the absence of other expression plasmids (data not shown). CAT activities observed in the presence of increasing amounts of dTBP expression plasmid were not affected by co-transfection of Nucleic Acids Research, 1996, Vol. 24, No. 21 4285 constant amounts of pACT53 (Fig. 4B) , ruling out the possibility that stimulation of basal activity was overcoming a repressive effect due to saturating levels of dTBP expression in the previous experiment. These results demonstrate that although p53 can repress activated transcription, it cannot affect either basal expression or basal expression stimulated by overexpressed TBP. Since TBP is required for both activated and basal transcription (reviewed in 43), these results provide evidence that an interaction between p53 and TBP is not sufficient for p53-mediated repression.
Overexpression of hTBP does not rescue transcriptional repression by p53
If p53 was exerting its repressive effects via its interaction with TBP, then it is conceivable that p53-mediated repression could be rescued by overexpression of TBP. Since it is known that hTBP is able to interact with both the N-and C-termini of p53 (48), while dTBP has only been shown to interact with the N-terminal domain of p53 (41), we thought it important to first investigate the possible effects of this version of TBP on p53-mediated repression. This is despite the weaker effect of hTBP than of dTBP in stimulating both basal and activated CAT expression. We have observed that dTBP and either GAL4-VP16 or Sp1 can synergistically stimulate CAT activity in Schneider cells (41) . Likewise, transfection of increasing amounts of the expression plasmid for hTBP stimulated GAL4-VP16-mediated and Sp1-mediated activation of CAT expression 7-to 10-fold ( Fig. 5A  and B ). This demonstrates that hTBP can cooperatively activate transcription with these activators in transfected Schneider cells. When a constant amount of pACT53 was co-transfected with the other transfection plasmids, overall activation was inhibited, consistent with previous results (Fig. 1) . While co-expressed hTBP continued to cooperate with GAL4-VP16 and Sp1 in activating CAT expression, it was unable to relieve the repression by p53 (Fig. 5A and B) . This was not due to altered levels of protein expression, since accumulation of both p53 and hTBP was not affected when both were expressed simultaneously (Fig. 5C ). Since different antibodies were used to detect p53 (PAb 421) and flu-epitope tagged hTBP (12CA5), the data shown do not reflect the absolute levels of p53 and tagged hTBP in transfected cells. The same result was observed when dTBP was substituted for hTBP (data not shown). Despite the fact that p53 has been shown to bind hTBP, this interaction appears insufficient to rescue transcriptional repression by p53. This provides further evidence that interactions distinct from those with TBP are involved in p53-mediated repression of activated transcription.
A p53 mutant defective in transcriptional activation is also defective in transcriptional repression
Our results suggest that an interaction between p53 and a factor other than TBP is necessary for transcriptional repression. A p53 mutant containing amino acid substitutions at residues Leu22 and Trp23 within its activation domain (p53 Gln22/Ser23 ) has been previously described and shown to be severely impaired in its ability to activate transcription in vivo (40) and in vitro (38, 39) . This mutant p53 has also been shown to be defective in its ability to bind Drosophila TAF II 40 and TAF II 60 as well as human TAF II 31 and TAF II 70 (38, 39) . However, this mutant is still able to bind hTBP (40, 41) and, importantly, able to bind dTBP via the N-terminus (41) . Therefore, we believed that results obtained due to expression of p53 (Gln22/Ser23) would be informative in investigating the p53-TBP interaction as it pertains to transcriptional repression.
Transfection experiments with p53 (Gln22/Ser23) demonstrated that this mutant was severely impaired in its ability to repress activation by GAL4-VP16 (Fig. 6A) and Sp1 (Fig. 6B) . This effect was not due to a lack of expression of p53 (Gln22/Ser23) , since it accumulates to levels equivalent to wild-type p53 in transfected Schneider cells (41) . Thus, the defect in binding TAF II 40 and TAF II 60 not only correlates with the ability of p53 to activate transcription (38) , but also with its ability to repress transcription. Since the mutation in p53 (Gln22/Ser23) does not impair the N-terminus of p53 from interacting with dTBP, this provides further confirmation of our hypothesis that repression by p53 is mediated via a mechanism distinct from binding TBP. Furthermore, since p53 (Gln22/Ser23) contains a non-functional activation domain, these results demonstrate that transcriptional repression by p53 is directly correlated with its ability to activate transcription. A simple hypothesis, then, is that p53-mediated repression results from squelching (63) of a specific co-activator(s).
DISCUSSION
In this study we demonstrate that p53 can serve as a repressor of activated transcription from reporter plasmids lacking p53 binding sites in transfected Drosophila Schneider cells. Investigation of this activity demonstrated that a direct interaction between p53 and TBP is not sufficient and that an interaction(s) with other factors is required. Three lines of evidence presented here support this contention: (i) p53 inhibited activated stimulation of CAT expression by three different transcriptional activators, but it did not affect the stimulation of basal CAT expression due to overexpression of dTBP or hTBP; (ii) overexpression of hTBP (or dTBP; data not shown) did not rescue the inhibition of activated CAT expression by p53; (iii) a mutant p53 defective in transcriptional activation in vivo but still capable of binding TBP did not repress activated CAT expression.
A problem with investigating the biological relevance of the TBP-p53 interaction stems from the lack of p53 mutants that are specifically defective in their interactions with TBP. Therefore, understanding whether this interaction is necessary and/or sufficient for transcriptional repression has been difficult to assess. Previous investigation of the p53-TBP interaction has further complicated this issue, revealing that at least two regions of p53 have the ability to bind TBP (35, 48) . One region was mapped between residues 20 and 57, spanning the transcriptional activation domain of p53. A GAL4 fusion protein lacking these residues did not activate transcription in transient transfection assays, leading to speculation that TBP binding via these residues is required for transactivation by p53 (35) . However, functional interactions between p53 and TAFs have also been mapped to this region (38, 39) , which would account for the inactivity of this mutant. The other TBP binding domain of p53 has been mapped to the last 75 amino acids of the C-terminus, a region that has not been shown to contain any transcriptional activation function (48) . However, this C-terminal region was found to repress transcription in both a DNA binding-independent (64) and a DNA bindingdependent (48) manner. This region is not sufficient for the repression we have observed, as the mutant p53 (Gln22/Ser23) protein was inactive.
Both TBP interaction domains of p53 have been shown to interact with the same region of TBP, mapping to residues 217-268 within its conserved C-terminus (48) . These data are somewhat complicated, since they would suggest that interactions involving the same region of TBP and two separate domains of p53 manifest opposite effects. The significance of the p53-TBP interaction is further complicated by two other independent studies investigating an interaction between p53 and yeast TBP (yTBP) (19, 37) . Seto et al. (19) reported that when a human cell extract containing heat inactivated hTBP was substituted by functional yTBP, the system was transcriptionally active and was no longer susceptible to repression by p53. Those authors also demonstrated that p53 did not bind yTBP, thereby accounting for the inability of p53 to repress transcription in this system. However, Truant et al. (37) reported that p53 can, in fact, bind yTBP. Hence, inconsistencies regarding the mechanism of p53 repression are apparent, specifically as to whether this activity is mediated via its interaction with TBP.
Our results have demonstrated that p53 (Gln22/Ser23) , previously shown to be defective in transcriptional activation and binding TAFs, is defective in repressing activated transcription by GAL4-VP16 and Sp1. However, p53 (His175) , a p53 mutant previously shown to be defective in DNA binding, was fully active in repression. These findings demonstrate that an intact transcriptional activation domain of p53 is required for transcriptional repression, but the ability to bind DNA is not. This suggests that transcriptional repression by p53 may be a form of squelching (63) , whereby one or more factors required for transcription are titrated out due to an excess of a transcriptional activator. Consistent with this idea, self-squelching of p53-mediated transcriptional activation itself has been observed in vitro, both in our laboratory (G. Farmer and C. Prives, unpublished results) and in others (65) . In fact, Liu and Berk (65) have reported that supplementation of intact TFIID (and TFIIB), but not recombinant hTBP, to an in vitro transcription system was able to rescue p53-mediated squelching of transcriptional activation by p53, suggesting that factors associated with TBP (e.g. TAFs) are most likely targets for this effect. Note, however, that the squelching we propose must have an element of specificity, as both basal expression and activated expression from the Inr-containing promoters are resistant to p53. In addition, although squelching is commonly thought to reflect a non-physiological interaction resulting from overexpression of a given activator, it remains possible that p53-mediated repression is a physiologically relevant mechanism when p53 levels are elevated.
Although our data suggest that interactions between p53 and TAFs mediate the repressive effects by overexpressed p53, they do not prove it. Co-activators that are not integral components of TFIID and which interact directly or indirectly with the p53 activation domain might be involved. This is an especially attractive possibility because p53 (Gln22/Ser23) is impaired in repressing activation by both GAL4-VP16 and Sp1. Since TAF II 40 has been shown to be involved in transcriptional activation by VP16 in vitro (66) and since p53 (Gln22/Ser23) cannot repress transactivation by GAL4-VP16 (this study) nor bind TAF II 40 (38) , it could be speculated that a TAF II 40-p53 interaction mediates transcriptional repression by p53. However, TAF II 40 has been shown to be unnecessary for Sp1-mediated transcriptional activation in vitro (67) . If these results reflect the situation in vivo, the defect in p53 (Gln22/Ser23) that impairs binding to TAF II 40 and TAF II 60, which is also unnecessary for Sp1-mediated activation in vitro (67) , may be unrelated to its inability to repress this activation. Nevertheless, regardless of whether direct interactions between TAFs and p53 are involved in p53-mediated transcriptional repression, it is clear that interactions distinct from those between p53 and TBP are responsible for this effect.
Our data raise interesting questions about the significance of transcriptional repression by p53. While cell cycle arrest is tightly correlated with the transcriptional activation function of p53, there are a number of reports indicating that the apoptotic function of p53 can, in some cases, be uncoupled from its transactivation function. Notably, Caelles et al. (32) and Wagner et al. (33) reported that p53-mediated apoptosis can occur in the presence of inhibitors of RNA synthesis. Furthermore, Haupt et al. (34) found that the transactivation defective mutant p53 (Gln22/Ser23) is capable of inducing apoptosis in HeLa cells. We have similarly observed that induction of mutant p53 (Gln22/Ser23) can induce apoptosis in human Saos 2 cells, although with delayed kinetics when compared with wild-type p53 (70) . Taken together these results indicate strongly that there is an activity of p53 which is independent of its ability to transactivate target genes that is sufficient to induce apoptosis in some cell types. Indeed, both Shen and Shenk (68) and Sabbatini et al. (69) found that two anti-apoptotic factors, adenovirus E1b 19 kDa protein and bcl2, can inhibit p53-mediated repression but not transactivation of reporter genes. One might therefore deduce from these different observations that p53-mediated repression correlates with apoptosis. Our data, however, with both transactivation defective mutant p53 (Gln22/Ser23) and DNA binding defective p53 (His175) show that a functional activation domain is required for its repression function, but not a functional sequence-specific DNA binding region. Thus, p53 (His175) (along with several other tumor-derived p53 mutants) is completely defective in inducing apoptosis (71) , while, as mentioned above, p53 (Gln22/Ser23) is at least partially competent in inducing apoptosis in some human cells (34, 70) . Admittedly, it is possible that the mutations in the p53 activation domain may affect other as yet unidentified interactions. Nevertheless, our data raise the possibility that another function of p53 might be involved in apoptosis, one that does not require its ability to repress transcription.
